FDA approves Lucentis to treat diabetic retinopathy in patients with diabetic macular edema

The U.S. Food and Drug Administration today expanded the approved use for Lucentis (ranibizumab injection) 0.3 mg to treat diabetic retinopathy (DR) in patients with diabetic macular edema (DME).

Source: Food and Drug Administration - February 6, 2015 Category: American Health Source Type: news